Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) is advancing its preclinical oncology candidate ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to disrupt DNA-repair mechanisms that enable cancer survival and treatment resistance. The company recently completed a 300-gram API scale-up with approximately 99.3% purity, a significant manufacturing milestone that demonstrates its ability to produce the drug at the quality and quantity needed for clinical translation.
To further bolster manufacturing capabilities, Onco-Innovations has entered a partnership with Nanosoft Polymers, expanding its capacity to produce ONC010 under current Good Manufacturing Practice conditions. This collaboration is essential for generating clinical-grade material for upcoming studies. Concurrently, the company is progressing metabolism, analytical, and licensing activities, as well as other Investigational New Drug (IND)-enabling work required to initiate human trials.
The company has also arranged approximately CAD$5 million in institutional financing, to be released through 18 monthly tranches. These funds will support ONC010 development, the SynoGraph platform, and general corporate needs. While the eventual proceeds may differ from the stated notional amount, the financing provides a steady capital stream to advance the program without immediate dilution pressures. The appointment of Dave Antony as Chief Financial Officer adds financial and corporate experience to the team as it navigates the complex regulatory and financial landscape of drug development.
These developments are critical because they position Onco-Innovations to move ONC010 into a planned Phase 1 study in Australia. The scale-up and purity achievement reduce manufacturing risks, while the financing and CFO appointment strengthen the company's operational and financial infrastructure. For investors, the progress signals a maturing pipeline that could address unmet needs in oncology, particularly for patients whose tumors resist conventional treatments.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumors. For more information, visit the company's website at https://oncoinnovations.com/. The latest news and updates relating to ONNVF are available in the company's newsroom at https://nnw.fm/ONNVF.
NetworkNewsWire (NetworkNewsWire), a specialized communications platform focused on financial news and content distribution, disseminated this announcement. It is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently reach target markets, as well as article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, and social media distribution via IBN to millions of followers. For more information, please visit https://www.NetworkNewsWire.com.
